Zynlonta Injection, Powder, Lyophilized, For Solution
Product Images NDC 79952-110

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Zynlonta (NDC 79952-110). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Adc Therapeutics America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Zynlonta 01)

Chemical structure diagram illustrating the conjugation of loncastuximab with the SG3249 drug-linker. The linker includes a valine-alanine dipeptide and an SG3199 PBD dimer component, depicting the molecular layout of this antibody-drug conjugate used in ZYNLONTA injection.*

FDA Label Image

Principal Display Panel (10 mg Vial Carton)

Packaging label for Zynlonta (loncastuximab tesirine-plyl) Injection, 10 mg/vial, lyophilized powder for solution. The label includes storage instructions, reconstitution directions, and cautions. Manufactured by ADC Therapeutics SA, Switzerland, the label displays dosing and handling warnings and the NDC 79952-110-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.